[Rectal carcinoma. Optimizing treatment by neoadjuvant and adjuvant therapy?].
Despite of improvement of results in rectum cancer treatment after systematical introduction of total mesorectal excision as a standard procedure to control the compartment disease, surgical radicality may be limited in cases with large tumours in ventral position because of eccentric location of the rectum in the perirectal fat. In these cases (neo)adjuvant treatment with a 45-54 Gy dose radiotherapy and 5 FU-based chemotherapy seems to be useful to minimize local recurrence and distant metastases and also to provide a better outcome.
Fasolini
F
F
Chirurgische Klinik, Kantonsspital Aarau.
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery
D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil
Rektumkarzinom. Optimierung durch neoadjuvante und adjuvante Therapie?